Dr. Hansen on the Utilization of BCMA-Directed Therapy in Multiple Myeloma

Partner | Cancer Centers | <b>Moffitt</b>

Doris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.

Doris Hansen, MD, assistant member, Moffitt Cancer Center department of blood and marrow transplant and cellular immunotherapy, discusses the utilization of BCMA-directed therapy in multiple myeloma.

his is an exciting time for the treatment of patients with multiple myeloma, as several agents have been approved in the past few years, Hansen says. However, patients have passive responses with some treatments, which causes them to relapse, Hansen adds.

Moreover, future progress with BCMA-directed therapies is indicative of disease or tumor burden; therefore, as you lower the level of tumor burden, patients tend to derive a durable and deeper type of response, Hansen continues. Although BCMA-targeted therapies should be continually utilized for patients, the future lies in identifying additional optimal targets for treatment, such as CD38 or GPRC5D, Hansen says. Utilizing novel targeted therapies elicit more durable responses, Hansen concludes.